2016年至2018年南京各级医院抗哮喘药物利用和可获得性分析  

Utilization and Availability of Anti-Asthma Drugs in Hospitals at All Levels in Nanjing from 2016 to 2018

作　　者：王璐璐[1] 戴惠珍 李歆[3,4] WANG Lulu;DAI Huizhen;LI Xin(Department of Pharmacy,Nanjing Drum Tower Hospial,The filiaed Hospial of Nanjing University Medical School,Nanjing,Jiangsu,China210008;Jiangsu Medicine Information Isitue,Nanjing,Jiangsu,China 210029;College of Pharmacy,Nanjing Medical Unitersity,Nanjing,Jiangsu,China 211166;Center for Global Health,School of Public Health,Nanjing Medical Unitersity,Nanjing,Jiangsu,China 211166)

机构地区：[1]南京大学医学院附属鼓楼医院药学部,江苏南京210008 [2]江苏省医药情报研究所,江苏南京210029 [3]南京医科大学药学院,江苏南京211166 [4]南京医科大学全球健康中心,江苏南京211166

出　　处：《中国药业》2021年第5期6-11,共6页China Pharmaceuticals

基　　金：国家自然科学基金面上项目[71673147]。

摘　　要：目的分析南京2016年至2018年抗哮喘药物的使用情况,促进临床合理使用。方法根据江苏省医药情报研究所提供的2016年至2018年南京56家医院抗哮喘药物的销售数据,采用金额排序法和用药频度分析法,回顾性分析抗哮喘药物的销售金额;所有抗哮喘药物用药频度(DDDs)和限定日费用(DDC)等,同时评价抗哮喘药物的可获得性。结果共涉及19个品种,销售金额排名前3位的药物分别为布地奈德、孟鲁司特钠和布地奈德福莫特罗;DDDs排名前3位的药物分别为沙美特罗替卡松、异丙托溴铵和孟鲁司特钠,总销售金额和总DDDs均呈增长趋势;除沙美特罗替卡松和异丙托溴铵外,其余药物销售金额与DDDs序号的比值均在0.17~2.00范围内;DDC排名前3位的药物分别为多索茶碱、特布他林和倍氯米松;各类抗哮喘药物在二、三级医院的可获得性均较高,在一级医院的可获得性极低。结论南京抗哮喘药物用量增长稳定,类别结构较完善,总体上可满足不同层次和类型哮喘患者的用药需求,但一级医院抗哮喘药物可获得性较低。为满足用药需求,应提高一级医院抗哮喘药物的可获得性。Objective To analyze the utilization of anti-asthma drugs in Nanjing from 2016 to 2018,and to promote the clinical rational use of anti-asthma drugs.Methods According to the sales data of anti-asthma drugs in 56 hospitals in Nanjing from 2016 to2018 provided by Jiangsu Institute of Medical Information,the utilization of anti-asthma drugs in Nanjing was analyzed retrospectively in respect of the consumption sum,defined daily doses(DDDs)and defined daily cost(DDC)by using amount analysis and drug frequency analysis.The availability of anti-asthma drugs was also evaluated.Results There are 19 varieties of anti-asthma drugs in Nanjing.The top three anti-asthma drugs in the list of consumption sum were budesonide,montelukast and budesonide formoterol.In terms of DDDs,salmeterol fluticasone,ipratropium bromide and montelukast ranked top three.The consumption sum and DDDs of all the anti-asthma drugs increased year by year in Nanjing.The ratio of serial number of consumption sum and DDDs of anti-asthma drugs was in the range of 0.17-2.00 except for salmeterol fluticasone and ipratropium bromide.The top three anti-asthma drugs in the list of DDC were doxofylline,terbutaline and beclometasone.The availability of anti-asthma drugs was relatively high in the secondary and tertiary hospitals,but very low in primary hospitals.Conclusion The dosage of anti-asthma drugs in Nanjing increases steadily,and the category structure is relatively perfect,which can generally meet the medication needs of patients with different levels and types of asthma.The availability of anti-asthma drugs in primary medical institutions is low.In order to meet the medication needs of patients,the availability of anti-asthma drugs in primary medical institutions should be improved.

关 键 词：抗哮喘药物 用药频度 销售金额 可获得性 合理用药 药事管理 南京 

分 类 号：R969.3[医药卫生—药理学] R974.3[医药卫生—药学]